Urticaria associated with hyper-IgE in a patient with psoriasis undergoing treatment with efalizumab.

@article{Saraceno2009UrticariaAW,
  title={Urticaria associated with hyper-IgE in a patient with psoriasis undergoing treatment with efalizumab.},
  author={Rosita Saraceno and Gea Scotto and Andrea Chiricozzi and Sergio Chimenti},
  journal={Acta dermato-venereologica},
  year={2009},
  volume={89 4},
  pages={412-3}
}
Sir, Efalizumab (Raptiva®) is a recombinant humanized monoclonal IgG1 antibody that binds to CD11a, the α-subunit of leukocyte function antigen-1 (LFA-1). CD-11a modulates several key steps in the immunopathogenesis of psoriasis, including initial T-cell activation, trafficking from the circulation into psoriatic lesions, and reactivation therein (1… CONTINUE READING